check quantity

Epic C18 LC Columns - 125 mm, 4.6 mm I.D., 5 μm

Epic C18 is a highly inert phase due to its superior base deactivation. As a result of the high-density bonding levels (> 4 µmol/m2), Epic C18 demonstrates superior peak shapes for the most demanding applications. This phase provides exceptional peak shape and selectivity over a wide range of compounds and pH and is the workhorse HPLC and UHPLC phase for RP small molecule analysis. It can be used with basic, neutral and acidic analytes.

Part Number
Inner Diameter
Particle Size
List Price
Your Price
75.0 mm
4.6 mm
3.0 µm
515.00 USD
125.0 mm
4.6 mm
5.0 µm
515.00 USD
200.0 mm
5 mm
5.0 µm
555.00 USD
Buy Now

Please enter valid quantity

Please log in to add favorites.



The Epic line our latest range of LC columns, based on high density monomerically bonded phases produced through a proprietary bonding process. Epic HPLC and UHPLC columns are compatible with a wide range of organic modifiers and buffers and stable over a wide pH range. All Epic products use an ultra-high purity metal free silica and undergo strict quality control testing. For flexibility, we offer a wide range of column sizes as well being fully scalable from analytical to preparative dimensions.

Features and Benefits:

  • Ultra-high purity silica for improved peak shape, especially for basic compounds
  • Extensive range of stationary phase chemistries with innovative bonding chemistry to enhance method development
  • High density bonding produces columns with better pH stability, increased sample loading and better lot-to-lot reproducibility
  • Extended pH stability across commonly used mobile phase buffers
  • Microbore to preparative dimensions available to allow flexibility and full scalability


Inner Diameter 4.6 mm
Length 125.0 mm
Particle Size 5.0 µm
Phase C18
Resources, Events & More
  • All

Application Brief

HPLC Analysis of Fluconazole Using an Epic C18 Column in Accordance with the USP

Fluconazole is an azole anti-fungal medication that is used to treat infections caused by fungus, which can invade any part of the body including the mouth, throat, esophagus, lungs, bladder, genital area, and the blood. Fluconazole is also used to prevent fungal infection in people who have a weak immune system caused by cancer treatment, bone marrow transplant, or diseases such as AIDS. The mechanism of action can be described as fungistatic, the growth and replication of fungi is inhibited by Fluconazole rather than directly attacked. This process is achieved by inhibiting the fungal cytochrome P450 dependent enzyme, lanosterol 14-a-demethylase, which is important in the production of fungal membranes, allowing the immune system ample opportunity to target and degrade the pathogen. Fluconazole is on the World Health Organization’s (WHO) list of essential medicines, which serves as a model of the safest and most effective medications needed by a health system.

This application brief describes the use of an Epic C18 column coupled with the LC 300 liquid chromatography system and SimplicityChrom chromatography data system (CDS) for the analysis of Fluconazole in accordance with the official USP monograph.

PDF 822 KB
HPLC Analysis of Levetiracetam Using Epic C18, Epic C18-SD, and Epic Polar Columns in Accordance with the USP

Levetiracetam was approved for medical use in the United States in 1999 and is available as a generic medication.1 Levetiracetam is a novel anticonvulsant agent used as an adjunct medication to manage partial onset, myoclonic, and generalized tonic-clonic seizures in patients with epilepsy. It is sold under the brand name Keppra, among others, and is a medication used to treat epilepsy. It is used for partial-onset, myoclonic, or tonic–clonic seizures and is taken either by mouth as an immediate or extended-release formulation or by injection into a vein. In 2018, it was the 97th most prescribed medication in the United States, with more than 7 million prescriptions. Levetiracetam is also available as an orally dissolvable tablet that is indicated as an adjunct in the treatment of partial onset seizures in patients with epilepsy who are 4 years of age and older and weigh more than 20 kg. Levetiracetam is being tested as a drug to reduce hyperactivity in the hippocampus in Alzheimer's disease.

The United States Pharmacopeia (USP) provides monographs for identification and impurity testing of the drug substance. This application brief describes use of an Epic C18, Epic C18 SD column (highly base deactivated high carbon super dense phase), and Epic Polar (all USP L1 columns) coupled with the LC 300 liquid chromatography system and SimplicityChrom chromatography data system (CDS) for the analysis of Levetiracetam as per the USP monograph.

PDF 361 KB
HPLC Analysis of Oleanolic Acid and Ursonic Acid in Eriobotrya Japonica Leaf

Eriobotrya japonica leaf is included in the Chinese Pharmacopoeia and is widely used as a medicinal material in traditional treatment of a variety of chronic diseases in China and other East Asian countries. Phytochemical investigations showed that its main components are essential oil, triterpenes, sesquiterpenes, flavonoids, tannins, and megastigmane glycosides. Among them, triterpene acids are considered as the key pharmacological components. To date, more than twenty triterpene acids in Eriobotrya japonica leaf have been identified, including the major four triterpene acids, that is, ursonic acid, corosolic acid, oleanolic acid, and maslinic acid, which belong to ursane type and oleanane type.

In the 2020 Edition of the Chinese Pharmacopeia, two marker compounds, oleanolic acid and ursonic acid are assayed by using an HPLC-UV method, which is important for quality control of this traditional Chinese medicine (TCM).